1. Trong, H. N.; Tat, T.N.; Anh, T.T.N.; Uyen, N.P.; Van, T.N.; Hau, K.T.; Gandolfi, M.; Satolli, F.; Feliciani, C.; Tirant, M.; Vojvodic, A.; Lotti, T. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis. Open Access Maced J Med Sci. 2019 Jan;7(2):237-242. doi:10.3889/oamjms.2019060. eCollection 2019 Jan 30.
2.Imamura, T.; Takata, I.; Ogasawara, M.; Matsutani, Y.; Yamamoto, T.; Asagami, C. Clofibrate treatment of psoriasis with hypertriglycemia-clinical, histological and laboratory analysis. Nihon Hifuka Gakkai Zasshi. 1991 May;101(6);623-8.
3.Singh, S.; Bhansali, A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016 Aug 17;16(1);12. doi: 10.1186/s12895-016-0049-y.
4.Xu, X.; Lin, L.; Chen, P.; Yu, Y.; Chen, S.; Chen, X.; Shao, Z. Treatment with liraglutide, a glucagon-like peptide-1 analogue, imporves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019 Apr; 150;167-173 doi: 10.1016/j.diabres.2019.03.002. Epub 2019 Mar 4.
5.Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Ann. Intern. Med. 2009, 151, W65–W94.
6.Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71.
7.Garschick, M., S.; Drenkova, K.; Barrett, T.J.; Schlamp, F.; Fisher, E.A.; Katz, S.; Jelic, S.; Neimann, A.L.; Scher, J.U.; Krueger, J.; berger, J.S. A Randomized Open-Label Clinical trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. J Invest Dermatol. 2022 Jun;142(6);1749-1752.e4. doi. 1016/j.jid.2021.07.190. Epub 2021 Nov.
8.Naseri, M.; Hadipour, A.; Sepaskhah, M.; Namazi, M.R. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med. 2010 Jan-Mar; 19(1):58-61. doi: 10.4314/njm.v19i1.54216.
9.Wolkenstein, P.; Revuz, J.; Roujeau, J.C.; Bonnelye, G.; Grob, J.J.; Bastuji-Garin, S. Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey. Dermatology. 2009;218(2):103-9. doi: 10.1159/000182258. Epub 2008 Dec 6.
10.Shirinsky, I.V.; Shirinsky, V.S. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol. 2007 Sep;57(3):529-31. doi: 10.1016/j.jaad.2007.05.040.
11.Soodgupta, D.; Kaul, S.; Kanwar, A.J.; Parsad, D. Modulation of LXR-αand the effector genes by Ascorbic acid and Statins in psoriatic keratinocytes. Mol Cell Biochem. 2014 Dec;3979(1-2):1-6. doi: 10.1007/s11010-014-2063-x. Epub 2014 Oct 5.
12.Garschick, M.S.; Block, R.; Drenkova, K.; Tawil, M.; James, G.; Brenna, J.T. Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis. Prostaglandins Leukot Essent Fatty Acids. 2022 May;180;102428. doi: 10.1016/j.plefa.2022.102428. Epub 2022 Apr 16.
13.Vasiuk, I.A.; Perlamutrov, I.N.; Shkol’nik, M.N.; Shkol’nik, E.L. Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension. Kardiologiia. 2010;50(3):37-46.
14.Chua, S.H.H.; Tioleco, G.M.S.; Dayrit, C.A.F.; Mojica, W.P.; Dofitas, B.L.; Frez, L.F. Atorvastatin as adjunctive therapy for chronic type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venerol Leprol. 2017 Jul-Aug;83(4):441-447. doi: 10.4103/ijdvl.IJDVL_425_16.
15.Faghihi, T.; Radfar, M.; Mehrabian, Z.; Ehsani, A.H.; Hemami, M.R. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy. 2011 Nov;31(11): 1045-50. doi: 10.1592/phco.31.11.1045.
16.Salman, M.A.; Ghiasi, M.; Farid, A.S.; Taraz, M.; Azizpour, A.; Mahmoudi, H. Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatol Ther. 2021 Sep;34(5):315075. doi: 10.1111/dth.15075. Epub 2021 Aug 19.
17.Aslam, S.; Khurshid, K.; Asad, F.; Rani, Z.; Pal, S.S.P. Efficacy and safety of simvastatin in chronic plaque psoriasis. Journal of Pakistan Association of Dermatologists 2013;23 (3):310-314.
18.Colsman, A.; Sticherling, M. Simvastatin in psoriasis: ambiguous effects. Acta Derm Venereol. 2010 Jul;90(4):411. doi: 10.2340/00015555-0852.
19.Cozzani, E.; Scaparro, M.; Parodi, A.; A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep. 2009 Dec 30; 3(4): 60-61. doi: 10.3315/jdcr.2009.1037.
20.Salna, M.P.; Singer, H.M.; Dana, A.N. Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. Case Rep Dermatol Med. 2017;2017:3418204. doi: 10.1155/2017/3418204. Epub 2017 Jul 31.
21.Jacobi, T.C.; Higher, A. A clinical dilemma while treating hypercholesterolemia in psoriasis. Br J Dermatol. 2003 Dec;149(6):1305-6. doi: 10.1111/j.1365-2133.2003.05675.x.
22.Vahlquist, C.; Olsson, A.G.; Lindholm, A.; Vahlquist, A. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta Derm Venereol. 1995 Sep;75(5):377-80. doi: 10.2340/0001555575377380.
23.Fisher, D.A.; Elias, P.M.; LeBoit, P.L. Exacerbation of Psoriasis by the Hypolipidemic Agent, Gemfibrozil. Arch Dermatol. 1988 Jun;124(6):854-5.
24.Bongartz, T.; Coras, B.; Vogt, T.; Scholmerlich, J.; Muller-Ladner, U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2005 Jan;44(1):126-9. doi: 10.1093/rheumatology/keh423. Epub 2004 Oct 12.
25.Shafiq, N.; Malhotra, S.; Pandhi, P.; Gupta, M.; Kumar, B.; Sandhu, K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005 Apr;44(4):328-33. doi: 10.1111/j.1365-4632.2005.02504/x
26.Lajevardi, V.; Hallaji, Z.; Daklan, S.; Abedini, R.; Goodarzi, A.; Abdolreza, M. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol. 2015 Jan;54(1):95-101. doi: 10.1111/ijd.12585. Epub 2014 Sep 10.
27.Abidi, A.; Rizvi, D.A.; Saxena, K.; Chaudhary, S.; Ahmad, A. The evaluation of efficacy and safety of methotrexate and pioglitazone psoriasis patients: A randomized, open-labeled, active-controlled clinical trial. Indian J Pharmacol. 2020 Jan-Feb; 52(1):16-22. doi: 10.4103/ijp.IJP_88_19
28.Mittal, R.; Malhotra, S.; Pandhi, P.; Kaur, I.; Dogra, S. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009 Apr;145(4):387-93. doi: 10.1001/archdermatol.2009.5.
29.Ghiasi, M.; Ebrahimi, S.; Lajevardi, V.; Taraz, M.; Azizpour, A. Efficacy and safety of pioglitazone plus phototherapy versus phototherapy in patients with plaque type psoriasis: a Double Blinded Randomized Controlled Trial. J Dermatolog Treat. 2019 Nov;30(7):664-667. doi: 10.1080/09546634.2018.1544702. Epub 2018 Dec 3.
30.Hafez, V.G.; Bosseila, M.; Halim, M.R.E.A.; Shaker, O.G.; Kamal, M.; Kareem, H.S. Clinical effects of ”pioglitazone”, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 2015 Jun;26(3):208-14. doi:10.3109/09546634.2014.932.324. Epub 2014 Jul 1.
31.Pershadsingh, H.A.; Benson, S.C.; Ellis, C.N. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. 2005 Nov-Dec;4(6):386-90. doi: 10.1111/j.1540-9740.2005.04434.x.
32.Ellis, C.N.; Barker, J.N.; Haig, A.E.; Parker, C.A.; Daly, S.; Jayawardene, D.A.; Avandia Psoriasis Study Group. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol. 2007;8(2):93-102. doi: 10.2165/00128071-200708020-00005.
33.Lin, L.; Xu, X.; Yu, Y.; Ye, H.; He, X.; Chen, S.; Chen, X.; Shao, Z.; Chen, P. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized controlled trial. J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392. Epub 2020 Sep 24.
34.Faurschou, A.; Knop, F.K.; Thyssen, J.P.; Zachariae, C.; Skov, L., Visboll, T. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014 Feb;51(1):147-50. doi: 10.1007/s00592-011-0359-9. Epub 2011 Dec 13.
35.Ahern, T.; Tobin, A-M.; Corrigan, M.; Hogan, A.; Sweeney, C.; Kirby, B.; O’Shea, D. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1440-3. doi: 10.1111/j.1468-3083.2012.04609.x. Epub 2012 Jun 13.
36.Faurschou, A.; Gyldenlove, M.; Rohde, U.; Thyssen, J.P.; Zachariae, C.; Skov, L.; Knop, F.K.; Vilsboll, T. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients—a randomized placebo- controlled trial. J Eur Acad Dermatol Venereoal. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20.
37.Buysschaert, M.; Tennstedt, D.; Preumont, V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004. Epub 2012 Jan 9.
38.Buysschaert, M.; Baeck, M.; Preumont, V.; Marot, L.; Hendrickx, E.; Van Belle, A.; Dumoutier, L.; Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014 Jul;171(1):155-61. doi: 10.1111/bjd.12886. Epub 2014 Jul 16.
39.Hogan, A.E.; Tobin, A.M.; Ahern, T.; Corrigan, M.A.; Gaoatswe, G.; Jackson, R.; O’Reilly, V.; Lynch, L.; Doherty, D.G.; Moynagh, P.N.; Kirby, B.; O’Connell, J.; O’Shea, D. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells, lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3. Epub 2011 Jul 9.
40.Reid, C.T.; Tobin, A.M.; Ahern, T.; O’Shea, D.; Kirby, B. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol. 2013 Jul;169(1):230-1. doi: 10.1111/bjd.12380.
41.Costanzo, G.; Curatolo, S.; Busa, B.; Belfiore, A.; Gullo, D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021; 2021:21-0007. doi: 10.1530/EDM-21-0007.
1. Trong, H. N.; Tat, T.N.; Anh, T.T.N.; Uyen, N.P.; Van, T.N.; Hau, K.T.; Gandolfi, M.; Satolli, F.; Feliciani, C.; Tirant, M.; Vojvodic, A.; Lotti, T. Efficacy of Adding Oral Simvastatin to Topical Therapy for Treatment of Psoriasis. Open Access Maced J Med Sci. 2019 Jan;7(2):237-242. doi:10.3889/oamjms.2019060. eCollection 2019 Jan 30.
2.Imamura, T.; Takata, I.; Ogasawara, M.; Matsutani, Y.; Yamamoto, T.; Asagami, C. Clofibrate treatment of psoriasis with hypertriglycemia-clinical, histological and laboratory analysis. Nihon Hifuka Gakkai Zasshi. 1991 May;101(6);623-8.
3.Singh, S.; Bhansali, A. Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol. 2016 Aug 17;16(1);12. doi: 10.1186/s12895-016-0049-y.
4.Xu, X.; Lin, L.; Chen, P.; Yu, Y.; Chen, S.; Chen, X.; Shao, Z. Treatment with liraglutide, a glucagon-like peptide-1 analogue, imporves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019 Apr; 150;167-173 doi: 10.1016/j.diabres.2019.03.002. Epub 2019 Mar 4.
5.Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Ann. Intern. Med. 2009, 151, W65–W94.
6.Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71.
7.Garschick, M., S.; Drenkova, K.; Barrett, T.J.; Schlamp, F.; Fisher, E.A.; Katz, S.; Jelic, S.; Neimann, A.L.; Scher, J.U.; Krueger, J.; berger, J.S. A Randomized Open-Label Clinical trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. J Invest Dermatol. 2022 Jun;142(6);1749-1752.e4. doi. 1016/j.jid.2021.07.190. Epub 2021 Nov.
8.Naseri, M.; Hadipour, A.; Sepaskhah, M.; Namazi, M.R. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med. 2010 Jan-Mar; 19(1):58-61. doi: 10.4314/njm.v19i1.54216.
9.Wolkenstein, P.; Revuz, J.; Roujeau, J.C.; Bonnelye, G.; Grob, J.J.; Bastuji-Garin, S. Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey. Dermatology. 2009;218(2):103-9. doi: 10.1159/000182258. Epub 2008 Dec 6.
10.Shirinsky, I.V.; Shirinsky, V.S. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol. 2007 Sep;57(3):529-31. doi: 10.1016/j.jaad.2007.05.040.
11.Soodgupta, D.; Kaul, S.; Kanwar, A.J.; Parsad, D. Modulation of LXR-αand the effector genes by Ascorbic acid and Statins in psoriatic keratinocytes. Mol Cell Biochem. 2014 Dec;3979(1-2):1-6. doi: 10.1007/s11010-014-2063-x. Epub 2014 Oct 5.
12.Garschick, M.S.; Block, R.; Drenkova, K.; Tawil, M.; James, G.; Brenna, J.T. Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis. Prostaglandins Leukot Essent Fatty Acids. 2022 May;180;102428. doi: 10.1016/j.plefa.2022.102428. Epub 2022 Apr 16.
13.Vasiuk, I.A.; Perlamutrov, I.N.; Shkol’nik, M.N.; Shkol’nik, E.L. Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension. Kardiologiia. 2010;50(3):37-46.
14.Chua, S.H.H.; Tioleco, G.M.S.; Dayrit, C.A.F.; Mojica, W.P.; Dofitas, B.L.; Frez, L.F. Atorvastatin as adjunctive therapy for chronic type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venerol Leprol. 2017 Jul-Aug;83(4):441-447. doi: 10.4103/ijdvl.IJDVL_425_16.
15.Faghihi, T.; Radfar, M.; Mehrabian, Z.; Ehsani, A.H.; Hemami, M.R. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy. 2011 Nov;31(11): 1045-50. doi: 10.1592/phco.31.11.1045.
16.Salman, M.A.; Ghiasi, M.; Farid, A.S.; Taraz, M.; Azizpour, A.; Mahmoudi, H. Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatol Ther. 2021 Sep;34(5):315075. doi: 10.1111/dth.15075. Epub 2021 Aug 19.
17.Aslam, S.; Khurshid, K.; Asad, F.; Rani, Z.; Pal, S.S.P. Efficacy and safety of simvastatin in chronic plaque psoriasis. Journal of Pakistan Association of Dermatologists 2013;23 (3):310-314.
18.Colsman, A.; Sticherling, M. Simvastatin in psoriasis: ambiguous effects. Acta Derm Venereol. 2010 Jul;90(4):411. doi: 10.2340/00015555-0852.
19.Cozzani, E.; Scaparro, M.; Parodi, A.; A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep. 2009 Dec 30; 3(4): 60-61. doi: 10.3315/jdcr.2009.1037.
20.Salna, M.P.; Singer, H.M.; Dana, A.N. Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. Case Rep Dermatol Med. 2017;2017:3418204. doi: 10.1155/2017/3418204. Epub 2017 Jul 31.
21.Jacobi, T.C.; Higher, A. A clinical dilemma while treating hypercholesterolemia in psoriasis. Br J Dermatol. 2003 Dec;149(6):1305-6. doi: 10.1111/j.1365-2133.2003.05675.x.
22.Vahlquist, C.; Olsson, A.G.; Lindholm, A.; Vahlquist, A. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta Derm Venereol. 1995 Sep;75(5):377-80. doi: 10.2340/0001555575377380.
23.Fisher, D.A.; Elias, P.M.; LeBoit, P.L. Exacerbation of Psoriasis by the Hypolipidemic Agent, Gemfibrozil. Arch Dermatol. 1988 Jun;124(6):854-5.
24.Bongartz, T.; Coras, B.; Vogt, T.; Scholmerlich, J.; Muller-Ladner, U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2005 Jan;44(1):126-9. doi: 10.1093/rheumatology/keh423. Epub 2004 Oct 12.
25.Shafiq, N.; Malhotra, S.; Pandhi, P.; Gupta, M.; Kumar, B.; Sandhu, K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005 Apr;44(4):328-33. doi: 10.1111/j.1365-4632.2005.02504/x
26.Lajevardi, V.; Hallaji, Z.; Daklan, S.; Abedini, R.; Goodarzi, A.; Abdolreza, M. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol. 2015 Jan;54(1):95-101. doi: 10.1111/ijd.12585. Epub 2014 Sep 10.
27.Abidi, A.; Rizvi, D.A.; Saxena, K.; Chaudhary, S.; Ahmad, A. The evaluation of efficacy and safety of methotrexate and pioglitazone psoriasis patients: A randomized, open-labeled, active-controlled clinical trial. Indian J Pharmacol. 2020 Jan-Feb; 52(1):16-22. doi: 10.4103/ijp.IJP_88_19
28.Mittal, R.; Malhotra, S.; Pandhi, P.; Kaur, I.; Dogra, S. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009 Apr;145(4):387-93. doi: 10.1001/archdermatol.2009.5.
29.Ghiasi, M.; Ebrahimi, S.; Lajevardi, V.; Taraz, M.; Azizpour, A. Efficacy and safety of pioglitazone plus phototherapy versus phototherapy in patients with plaque type psoriasis: a Double Blinded Randomized Controlled Trial. J Dermatolog Treat. 2019 Nov;30(7):664-667. doi: 10.1080/09546634.2018.1544702. Epub 2018 Dec 3.
30.Hafez, V.G.; Bosseila, M.; Halim, M.R.E.A.; Shaker, O.G.; Kamal, M.; Kareem, H.S. Clinical effects of ”pioglitazone”, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat. 2015 Jun;26(3):208-14. doi:10.3109/09546634.2014.932.324. Epub 2014 Jul 1.
31.Pershadsingh, H.A.; Benson, S.C.; Ellis, C.N. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. 2005 Nov-Dec;4(6):386-90. doi: 10.1111/j.1540-9740.2005.04434.x.
32.Ellis, C.N.; Barker, J.N.; Haig, A.E.; Parker, C.A.; Daly, S.; Jayawardene, D.A.; Avandia Psoriasis Study Group. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol. 2007;8(2):93-102. doi: 10.2165/00128071-200708020-00005.
33.Lin, L.; Xu, X.; Yu, Y.; Ye, H.; He, X.; Chen, S.; Chen, X.; Shao, Z.; Chen, P. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized controlled trial. J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392. Epub 2020 Sep 24.
34.Faurschou, A.; Knop, F.K.; Thyssen, J.P.; Zachariae, C.; Skov, L., Visboll, T. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014 Feb;51(1):147-50. doi: 10.1007/s00592-011-0359-9. Epub 2011 Dec 13.
35.Ahern, T.; Tobin, A-M.; Corrigan, M.; Hogan, A.; Sweeney, C.; Kirby, B.; O’Shea, D. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1440-3. doi: 10.1111/j.1468-3083.2012.04609.x. Epub 2012 Jun 13.
36.Faurschou, A.; Gyldenlove, M.; Rohde, U.; Thyssen, J.P.; Zachariae, C.; Skov, L.; Knop, F.K.; Vilsboll, T. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients—a randomized placebo- controlled trial. J Eur Acad Dermatol Venereoal. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629. Epub 2014 Aug 20.
37.Buysschaert, M.; Tennstedt, D.; Preumont, V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004. Epub 2012 Jan 9.
38.Buysschaert, M.; Baeck, M.; Preumont, V.; Marot, L.; Hendrickx, E.; Van Belle, A.; Dumoutier, L.; Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study. Br J Dermatol. 2014 Jul;171(1):155-61. doi: 10.1111/bjd.12886. Epub 2014 Jul 16.
39.Hogan, A.E.; Tobin, A.M.; Ahern, T.; Corrigan, M.A.; Gaoatswe, G.; Jackson, R.; O’Reilly, V.; Lynch, L.; Doherty, D.G.; Moynagh, P.N.; Kirby, B.; O’Connell, J.; O’Shea, D. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells, lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3. Epub 2011 Jul 9.
40.Reid, C.T.; Tobin, A.M.; Ahern, T.; O’Shea, D.; Kirby, B. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol. 2013 Jul;169(1):230-1. doi: 10.1111/bjd.12380.
41.Costanzo, G.; Curatolo, S.; Busa, B.; Belfiore, A.; Gullo, D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021; 2021:21-0007. doi: 10.1530/EDM-21-0007.